• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Infrastructure Infrastructure

Infrastructure

Access to world-class infrastructure from discovery through commercialization.

At Aurigene, we have the world-class infrastructure to provide end-to-end services (from discovery through commercialization) to our clients. We operate state-of-the-art R and D and manufacturing facilities that are audited by major international regulatory agencies. The R and D facilities are in Hyderabad and Bangalore with a total built area of over 300,000 Sq.m. This facility is equipped with multiple fume hoods and special-purpose labs such as:

Peptide laboratory Oligonucleotide laboratory High potent laboratory Kilo labs for scale-up

The R and D facilities also house state-of-the-art analytical infrastructure and safety study labs. We have access to 8 cGMP API manufacturing sites with over thousands of kilo liter capacity. Our manufacturing facilities can handle a variety of unit operations and multiple technologies such as steroids, peptides, high potent APIs, carbohydrates and mPEGs.

We operate our facilities by international sustainability frameworks and our efforts in sustainability are recognized by DJSI (Dow Jones Sustainability Indices), FTSE4Good Index, CDP (Carbon Disclosure Project), S&P BSE Carbonex, S&P BSE Greenex, Bloomberg Gender-Equality Index

Speak to our experts

Infrastructure

Discovery Chemistry

Know More

Biology Services

Know More

API Development

Know More

API Manufacturing

Know More

Biotherapeutics Discovery

Know More

Biotherapeutics Development and Manufacturing

Know More

Formulation Services

Know More

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack